ICMR to test efficacy of two medicines for tackling drug-resistant TB

Tuesday, May 16, 2017

New Delhi: The Indian Council of Medical Research (ICMR) is planning to test the efficacy of two medicines — Metformin and Bedaquiline Delaminate — for tackling the drug-resistant tuberculosis.

Metformin is widely used to treat type-II diabetes. ICMR now plans a clinical trial to examine its effectiveness in fighting the TB microbe following encouraging scientific results from Indian biologists, reports Deccan Herald.

Bedaquiline, which received the US Food and Drug Administration’s approval in 2012 for the treatment of drug-resistant TB cases, is yet to be used in India’s public-funded national TB control programme.

The Metformin trial is expected to start in a couple of months, while the Bedaquiline trial may take about six months to kick off, according to ICMR director general Dr Soumya Swaminathan.

Categories: NEWS, Pharmaceuticals

Tags: , , , ,

  More from NEWS

Indian pharmaceutical market to reach $56 billion in 2020

India’s ‘first women hospital’ inaugurated in Delhi

Ability to provide sight being shifted from corneal surgeries to newer technologies

Govt may reduce seats in surgical super-speciality courses that fail to attract doctors

New AI able to identify & predict development of cancer symptom clusters

Humira approved in Japan for treatment of Hidradenitis Suppurativa

1 Comment »

Comment by shivani gour
2017-05-30 19:46:03

90 percent of population grows up deficient in Vitamin D3, which is involved in keeping our immune system intact. Yet no study mentions this as its not lucrative enough and plus supplementation will genuinely improve health )Which may not be the real aim of those who fund)

Name (required)
E-mail (required - never shown publicly)
Your Comment (smaller size | larger size)
You may use <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong> in your comment.